Kristen Kluska

Stock Analyst at Cantor Fitzgerald

(4.40)
# 377
Out of 4,711 analysts
204
Total ratings
42.25%
Success rate
31.33%
Average return

Stocks Rated by Kristen Kluska

Aquestive Therapeutics
Dec 17, 2024
Initiates: Overweight
Price Target: $17
Current: $3.65
Upside: +365.75%
Esperion Therapeutics
Dec 17, 2024
Initiates: Overweight
Price Target: $8
Current: $2.19
Upside: +265.30%
uniQure
Dec 10, 2024
Maintains: Overweight
Price Target: $28$58
Current: $16.98
Upside: +241.58%
Rigel Pharmaceuticals
Dec 10, 2024
Maintains: Neutral
Price Target: $15$25
Current: $17.09
Upside: +46.28%
Codexis
Nov 22, 2024
Reiterates: Overweight
Price Target: $11
Current: $5.28
Upside: +108.33%
Taysha Gene Therapies
Nov 14, 2024
Reiterates: Overweight
Price Target: $7
Current: $1.85
Upside: +278.38%
Capricor Therapeutics
Nov 14, 2024
Maintains: Overweight
Price Target: $25$30
Current: $13.07
Upside: +129.53%
Amicus Therapeutics
Nov 7, 2024
Maintains: Overweight
Price Target: $20$21
Current: $9.80
Upside: +114.29%
Sarepta Therapeutics
Nov 7, 2024
Upgrades: Overweight
Price Target: $152$167
Current: $118.97
Upside: +40.37%
Ultragenyx Pharmaceutical
Nov 6, 2024
Reiterates: Overweight
Price Target: $116
Current: $44.22
Upside: +162.32%
Reiterates: Overweight
Price Target: $18
Current: $5.70
Upside: +215.79%
Reiterates: Overweight
Price Target: $85
Current: $64.50
Upside: +31.78%
Reiterates: Overweight
Price Target: $7
Current: $3.35
Upside: +108.96%
Reiterates: Overweight
Price Target: $14
Current: $2.70
Upside: +418.52%
Reiterates: Overweight
Price Target: $67
Current: $45.18
Upside: +48.30%
Reiterates: Overweight
Price Target: $64
Current: $46.24
Upside: +38.41%
Reiterates: Overweight
Price Target: $13
Current: $4.64
Upside: +180.17%
Reiterates: Overweight
Price Target: $29
Current: $7.94
Upside: +265.24%
Reiterates: Overweight
Price Target: $67
Current: $25.14
Upside: +166.51%
Reiterates: Overweight
Price Target: $20
Current: $17.40
Upside: +14.94%
Downgrades: Neutral
Price Target: n/a
Current: $4.35
Upside: -
Reiterates: Overweight
Price Target: $5
Current: $0.61
Upside: +717.93%
Reiterates: Overweight
Price Target: $21
Current: $1.29
Upside: +1,527.91%
Reiterates: Overweight
Price Target: $6
Current: $0.56
Upside: +975.27%
Downgrades: Neutral
Price Target: $90$20
Current: $1.44
Upside: +1,288.89%
Reiterates: Overweight
Price Target: $23
Current: $3.10
Upside: +641.94%
Reiterates: Overweight
Price Target: $18
Current: $0.17
Upside: +10,627.06%
Maintains: Overweight
Price Target: $44$41
Current: $0.95
Upside: +4,215.79%
Initiates: Overweight
Price Target: $400
Current: $4.70
Upside: +8,410.64%
Downgrades: Neutral
Price Target: $1,250$85
Current: $2.48
Upside: +3,327.42%
Initiates: Overweight
Price Target: $70
Current: $0.49
Upside: +14,185.71%
Initiates: Overweight
Price Target: $45
Current: $1.68
Upside: +2,578.57%
Downgrades: Neutral
Price Target: $15$11
Current: $0.77
Upside: +1,320.64%
Initiates: Overweight
Price Target: $60
Current: $3.80
Upside: +1,478.95%
Initiates: Overweight
Price Target: $90
Current: $1.35
Upside: +6,566.67%
Assumes: Overweight
Price Target: $10,620$2,520
Current: $3.05
Upside: +82,522.95%
Initiates: Overweight
Price Target: $160
Current: $0.62
Upside: +25,706.45%